Note that AIM2 can activate inflammasomes in GC patients and act as a tumor suppressor by inducing IL-18 and IL-1β [25], indicating that AIM2 is an important prognostic indicator in GC patients, which is consistent with our study. This evidence concerns the gene IL18 and gastric cancer.